Agile raises $45 million to fund late-stage testing of low-dose contraceptive patch
This article was originally published in Scrip
Executive Summary
Agile Therapeutics has raised $45 million in a series B financing that will allow the US firm to fund Phase III development of its lead contraceptive patch AG200-15, and to advance its second contraceptive patch, AG1000, into Phase II development.